INTRODUCTION {#sec0005}
============

Alzheimer's disease (AD) is a progressive neurodegenerative condition and the leading cause of dementia among the elderly \[[@ref001]\]. AD can segment into two classifications depending on age at diagnosis, raising the possibility of different initiators of disease for each group. Late onset AD (LOAD) is the most prevalent form, a condition which affects those over the age of 65 and accounts for approximately 90 to 95% of all those diagnosed with AD. Early onset AD (EOAD) typically affects those under the age of 65 and is much rarer, accounting for just 5% to 10% of all AD cases \[[@ref002]\].

The genetic explanation for LOAD is complex with a growing number of different genes implicated, reviewed by \[[@ref003]\], yet none in isolation fully accounts for disease susceptibility. EOAD however can be sub-divided into two groups, familial and sporadic. Familial AD (fAD) is thought to be easier to explain, driven by mutations within a growing list of different genes, including but not limited to amyloid protein precursor (*APP*) or presenilin (*PSEN1* and *PSEN2*) genes \[[@ref002]\]. Sporadic EOAD (sEOAD), although like fAD occurs in individuals under the age of 65, has proven much harder to pin to any one gene or pathway. Comparative transcriptomic analysis of sEOAD and fAD brain tissue identified over 3000 differentially expressed genes \[[@ref005]\], suggesting sEOAD and fAD may be distinct neurodegenerative processes.

An increasing number of genes link with LOAD, an association identified through comparative genome wide association data analysis (GWAS) \[[@ref006]\]. These new studies link numerous pathways to pathogenesis, correlating genes and cellular processes not previously considered relevant \[[@ref006]\]. Current models suggest LOAD may be a complex multifactorial condition driven by a number of different genes located within independent pathways \[[@ref003]\]. Although each genetic variant links to disease, frequency within the wider population can vary; even the most common LOAD risk APOE *ɛ*4 allele only presents in 40% of LOAD patients. Diversity in the frequency of genetic drivers of AD may be considered surprising given the similarities in the pathology of the disease collectively among AD sufferers. One plausible hypothesis is that these genes could be differentially regulated within groups of AD suffers, existing within the population as variants at an epigenetic or regulatory level. Some data exists to support this notion. Differences in DNA methylation of AD associated genes have been identified in DNA samples taken from both the blood and the brain of patients diagnosed with LOAD \[[@ref007]\]. Notably *APP* has been found to be differentially methylated within the promoter region in LOAD, while sirtuin1 (*SIRT1*) has been shown to be differential methylated in a Chinese AD population \[[@ref013]\]. Little, however, is currently known about the epigenetic status of genes that associate with sEOAD.

Stable changes in DNA methylation can be induced by a person's lifestyle or environment and may progressively accumulate over many years. Levels of methylation may direct gene expression leading to changes in the levels of proteins, which may cause, drive, or exacerbate AD disease symptoms \[[@ref016]\]. Initial epi-profiling already undertaken using LOAD samples suggests this hypothesis may be correct for later onset AD \[[@ref007]\]; however, little work to date has been undertaken to investigate any putative epigenetic link with sEOAD. We therefore sought to investigate if those LOAD genes genetically associated with AD occur as epi-variants in sEOAD.

Genes previously associated with LOAD through GWAS profiling are likely candidates for epi-profiling with variation encoded by methylation. Genes already profiled using genetic association with LOAD include but are not limited to *PTK2*β, *ABCA7*, and *MEF2C* \[[@ref018]\]. These three genes are all implicated in a range of pathways associated with AD pathology. PTK2β functions in memory formation and cell proliferation and survival \[[@ref019]\], ABCA7 has a role in regulating AβPP processing and inhibiting amyloid-β \[[@ref021]\], while MEF2C is a transcription factor involved in preventing excessive synapse formation \[[@ref024]\].

Another gene, a candidate target of interest for both genetic and epigenetic analysis, is *SIRT1*. This gene is functionally implicated in AD disease pathology in a number of studies \[[@ref025]\]. Disease linked differential methylation of a non-coding region of *SIRT1* has already been demonstrated in peripheral blood leukocytes of a Chinese LOAD population \[[@ref013]\], therefore a comparative approach investigating sEOAD could be informative. Previous research by Hou et al. \[[@ref013]\] identified two CpGs outside of the promoter CpG Island (CGI) to be significantly hypermethylation in LOAD samples; this suggests that epi-profiling should not just be restricted to CpG repeats, exploring the wider gene region may reveal interesting information around regulation linked to disease.

There is some evidence to suggest that investigating regulatory features other than the promoter region could be productive. A 3'UTR CGI found within the *RIN3* gene is located on chromosome 14 and sits between two AD associated genes *SLC24A4* and *LGMN* \[[@ref018]\]. *RIN3* is interesting in isolation as this gene associates with AD pathology through its interaction with *BIN1*, a gene that shows the second most significant LOAD score after *APOE* \[[@ref029]\]. Further it has also been found to be differentially methylated in LOAD \[[@ref008]\]. It is likely that BIN1 and RIN3 interact in the process of endocytosis negatively effecting amyloid trafficking \[[@ref030]\]. Since 3' UTR methylation has recently emerged as an important epigenetic mark influencing gene expression, transcriptional elongation and splicing it is a valid hypothesis that this CGI may represent an informative target for epi-profiling \[[@ref032]\].

To date most transcriptomic or proteomic analysis is conducted using brain tissue. While profiles obtained from brain material may be informative about the direct epigenetic consequences of AD pathology, this tissue it is not a viable source for the identification of new biomarkers. Also it is well established that brain methylation can differ significantly between the different regions of the brain \[[@ref012]\]. Additional technical limitations include a restriction on test subject numbers through limited availability of tissue. Interestingly leukocytes are thought to acquire epigenetic markers linked to disease as they transit through the afflicted tissue. In limited studies to date, peripheral blood DNA methylation has been shown to be representative of brain methylation \[[@ref035]\]. Blood based epigenetic biomarkers may be a useful addition to the AD diagnostic tool kit available, while also informing on the fundamental biology of sEOAD.

This study profiles comparative levels of methylation present in individuals presenting with sEOAD. Through profiling DNA extracted from both blood and brain, we have identified variation in the methylation of key genes that may link to AD and the progression of sEOAD. Differences in methylation may be consistent across many CpGs or could be restricted to a single bp.

MATERIALS AND METHODS {#sec0010}
=====================

DNA samples {#sec0015}
-----------

sEOAD DNA samples were obtained from the Alzheimer's Research UK Consortium DNA Bank, a resource curated by the University of Nottingham and were either extracted from leukocytes (*n* = 51) or brain (cortex) (*n* = 24). In total 40 sEOAD and 21 control samples were used. 25 blood and 14 cortex brain AD samples and 26 blood and 10 brain control samples were used (See [Table 1](#adr-1-adr170015-t001){ref-type="table"} for further information). DNA samples used in this study have been genetically tested by Alzheimer's Research UK Consortium DNA Bank and none contained fAD mutations.

###### 

Shows clinical features of AD and control samples

  Group              Sex M/F    Age at death     Age at onset of disease   Age at sampling
  ------- --------- --------- ----------------- ------------------------- -----------------
  Blood      AD       17/8     57.95 (SD 3.28)       48.6 (SD 2.98)        47.2 (SD 2.28)
           Control    13/13          N/A                   N/A              82.8 (SD 4.5)
  Brain      AD       4/10     59.35 (SD 6.95)       48.85 (SD 3.32)       59.35 (SD 6.95)
           Control     6/4     84.2 (SD 3.55)              N/A             84.2 (SD 3.55)

All samples used in this study were received with informed consent and experimental procedures were approved by the local ethics committee, Nottingham Research Ethics Committee 2 (REC reference 04/Q2404/130). All experimental procedures were conducted in accordance with approved guidelines.

DNA extraction {#sec0020}
--------------

Approximately 200 mg of cortex tissue was chopped finely on dry ice then transferred to a 1.5 ml Eppendorf tube. This was then incubated overnight (∼18 h, shaking at 380 rpm, 50°C) with 500 μl AL lysis buffer and 50 μl proteinase K (both Qiagen) and 10 μl RNase A. Next, 500 μl of refrigerated phenol chloroform was added to the sample (Sigma), which was mixed by inverting before being subjected to centrifugation for 5 min at 13,000 rpm. The top phase of the resultant sample was then removed to a clean lock phase-gel 2 ml Eppendorf, and the addition of phenol chloroform, mixing and centrifugation repeated. The top phase of this was removed, and has 3 M sodium acetate (pH 5.2) added to it in a 1 : 9 ratio of sodium acetate to the sample. Chilled 100% ethanol was then added, at an equal volume to the sample, to precipitate out the DNA. Following centrifugation at 13,000 rpm for 15 min, a wash was performed using 500 μl 70% ethanol, before another centrifugation step, for 15 min (13,000 rpm). The remaining ethanol was then discarded and the pellet air-dried, before resuspension in 100 μl 1xTE buffer, by heating to 50°C for 1 h.

Bisulphite treatment {#sec0025}
--------------------

First DNA was bisulphite-treated using the EpiTect Bisulphite Conversion Kit (Qiagen, Germany), following the manufacturer's instructions. Bisulphite treatment converted any non-methylated cytosines to uracil; therefore, in the following PCR product, non-methylated cytosines became thymine, allowing pyrosequencing of the PCR product to result in identification of cytosine methylation. 500 ng of genomic DNA was bisulphite-treated for each patient sample and 10 ng of converted DNA was used in subsequent PCRs.

In silico methods {#sec0030}
-----------------

Target regions were identified using the UCSC Genome Browser (University of California, Santa Cruz, CA, USA) (<http://www.genome.ucsc.edu/index>). Pyrosequencing primers were then designed for these regions using the PyroMark Assay Design software version 2.0 (Qiagen) and obtained from Eurofins MWG. Pyrosequencing assays were designed using the PyroMark Q24 software.

Polymerase chain reaction (PCR) {#sec0035}
-------------------------------

PCRs were conducted using the PyroMark PCR Kit (Qiagen, Germany) following manufactures instructions. PCRs contained 12.5 μl PyroMark PCR Mastermix 2x (Qiagen), 2.5 μl CoralLoad Concentrate 10x (Qiagen), 0.25 ng of each PCR primer, and 10 ng DNA, made up to 25 μl with RNase-free water. Details of PCR primers can be found in [Supplementary Table 1](#S1){ref-type="supplementary-material"}; all PCR primer pairs contained a biotinylated primer to result in a biotinylated PCR product which could be captured by sepharose coated beads during pyrosequencing. PCR programs varied depending on primers used; details can be found in [Supplementary Table 2](#S1){ref-type="supplementary-material"}. PCR product quality was assessed by running 5 μl of PCR product on a 1% agarose gel prior to pyrosequencing.

Pyrosequencing {#sec0040}
--------------

A pyrosequencing platform Q24 pyrosequencer (Qiagen, Germany) with PyroMark Gold Q24 Reagents (Qiagen, Germany) was used to determine percentage methylation. Pyrosequencing was carried out following manufacturer's instructions/protocol. Pyrosequencing results were interpreted using the PyroMark Q24 software.

Statistical analysis {#sec0045}
--------------------

For all the methylation percentage data, one-way analyses of variance were used to test the blood and brain tissue data for differences between the AD and control groups of subjects. Each of the cytosines were analyzed separately as were the blood and brain tissue data sets. When multiple values were recorded for the same cytosine from the same subject, the values were averaged to produce one value per person for each cytosine. These averages were then analyzed using the Analysis of Variance routines within the Genstat18 statistical package.

The residuals from each analysis were plotted to check the assumptions of normality and homogeneity of residuals, and also to highlight possible rare variants. For rare variants, the probability of obtaining residual values as, or more, extreme than the one observed was calculated from the standard normal distribution curve. To achieve this, the residual deviation between the individual outlier and the mean of its group; and the overall standard deviation from the rerun analysis were used as input to the Genstat Normal probability distribution routine.

RESULTS {#sec0050}
=======

PTK2β, ABCA7, SIRT1, and the MEF2C promoter CGI showed no significant methylation in AD {#sec0055}
---------------------------------------------------------------------------------------

*PTK2*β*, ABCA7,* and *MEF2C*: Promoter regions of AD candidate genes *PTK2*β*, ABCA7, MEF2C*, and *SIRT1* were chosen as targets for analysis (see [Supplementary Table 1](#S1){ref-type="supplementary-material"} and [Supplementary Figure 1](#S1){ref-type="supplementary-material"}); initial gene targets were selected based on previously published GWAS risk analysis data \[[@ref018]\] or in the case of *SIRT1*, published promoter methylation data \[[@ref013]\]. Previous research identified *PTK2*β*, ABCA7*, and *MEF2C* to be associated with LOAD through GWAS \[[@ref018]\]; however, to date few experiments have investigated the contribution of these genes to sEOAD. These genes may be considered prime candidates for regulation via an epigenetic mechanism; therefore, we first chose to profile methylation at these loci in blood and brain tissue taken from sEOAD patients.

For *PTK2*β, *ABCA7*, and *MEF2C*, the CpG island closest to the start site of transcription was chosen for analysis (details in [Supplementary Figures 1 and 2](#S1){ref-type="supplementary-material"}). In total, we profiled 5, 8, and 4 CpGs for *PTK2*β*, ABCA7*, and *MEF2C*, respectively; however, unexpectedly, we failed to detect any significant difference in the average regional level of methylation across genes investigated in sEOAD blood or brain derived samples ([Fig. 1](#adr-1-adr170015-g001){ref-type="fig"}) (*p* \> 0.05). It is interesting to note that for *PTK2*β*, ABCA7*, and *MEF2C,* the regions targeted showed relatively low average levels of methylation in cortex and blood tissue of both AD and control samples.

![Box plots showing data representing average methylation across the regions investigated for *PTK2*β (A), *ABCA7* (B), *SIRT1* (C), and the *MEF2C* promoter CGI (D). No significant difference in methylation was observed between AD and control in either blood or brain tissue. Box plots represent median with 25th and 75th percentile as edges, the whiskers either show the lowest and highest values or extend to the first quartile minus the interquatile range multiplied by 1.5 and up to the third quartile add the interquartile range times 1.5, depending on which values are largest or smallest (for the top and bottom whiskers respectively). For *PTK2*β control blood *n* = 6, AD blood *n* = 5, control brain *n* = 3, and AD brain *n* = 4. For *ABCA7* control blood *n* = 7, AD blood *n* = 4, control brain *n* = 3, AD brain = 6. For *SIRT1* control blood *n* = 4, AD blood *n* = 5, control brain *n* = 3, and AD brain *n* = 3. For the *MEF2C* CGI region Control blood *n* = 3, AD blood *n* = 5, Control brain *n* = 3, AD brain *n* = 4.](adr-1-adr170015-g001){#adr-1-adr170015-g001}

Given the absence of variation we observed for *PTK2*β, *ABCA7*, and *MEF2C*, we opted to profile levels of methylation at an AD linked loci previously reported to be differentially methylated \[[@ref013]\]. *SIRT1* associates with AD pathology through its role in attenuating Aβ toxicity and preventing tau cytotoxicity \[[@ref025]\]; therefore, it is reasonable to suggest aberrant methylation may impede this protective effect. As this previous study was undertaken using samples obtained from LOAD patients, we chose to investigate if the epigenetic variation previously reported could also be observed in sEOAD patients. In order to directly compare levels of methylation for our sEOAD sample library with a previously published candidate AD associated epi-loci, we profiled two CpGs reported to be hypermethylated in LOAD peripheral blood \[[@ref013]\]. Where tested, we found no significant difference in methylation compared to controls at either CpG site in blood.

Methylation at the resolution of individual CpGs {#sec0060}
------------------------------------------------

We detected no difference in the average regional level of methylation for each of the four candidate genes tested and no significant difference in methylation was identified for any individual CpG duplet within CpG islands upstream of *ABCA7, SIRT1* or *MEF2C* in either tissue (*p* \> 0.05; [Supplementary Figure 3](#S1){ref-type="supplementary-material"}). However, interestingly, one specific CpG site investigated within the *PTK2*β promoter CGI showed significant hypermethylation in AD blood (*p* = 0.04) but not AD cortex (*p* = 0.47) ([Fig. 2](#adr-1-adr170015-g002){ref-type="fig"}). The average methylation found at CpG1 in AD blood was 8.4% compared to 5% in control blood. Although statistically significant, and all samples were completed in duplicate, it should be noted that this difference is relatively small \[[@ref037]\].

![*PTK2*β shown at resolution of individual CpG: For the target region investigated in the *PTK2*β promoter CpG1 was found to be significantly hypermethylated in AD Blood but not AD brain. Average methylation at each CpG investigated in controls (white bar) and AD (black bar) in blood (A) and brain (B) is shown, error bars represent S.E.M. ^\*^*p* \< 0.05 (one tailed *T*-test). For blood control *n* = 6 AD = 5, for brain control *n* = 3, AD *n* = 4.](adr-1-adr170015-g002){#adr-1-adr170015-g002}

MEF2C Epi-variant CpG upstream of promoter CGI investigated {#sec0065}
-----------------------------------------------------------

CpGs located within the CpG island upstream of the transcription start site of *MEF2C(1),* (see [Fig. 3](#adr-1-adr170015-g003){ref-type="fig"}), show equivalent levels of methylation between AD and control samples. However, it is plausible that methylation located at other upstream CpGs outside of this location may be crucial in determining either levels of transcription or the structure of the transcript expressed, therefore a further CpG site was targeted (shown as *MEF2C(2)* in [Fig. 3](#adr-1-adr170015-g003){ref-type="fig"}). As a group wide average, there was no evidence of a difference between the AD and control groups in either the blood (*p* = 0.708) or cortex (*p* = 0.593) data set ([Fig. 3](#adr-1-adr170015-g003){ref-type="fig"}). Average levels of methylation were substantially higher than those of the other genes tested; average methylation of 91% in blood and 86% in brain average. No significant difference in methylation was observed between the tissue types (*p* \> 0.05) ([Supplementary Figure 4](#S1){ref-type="supplementary-material"}).

![(A) Diagram showing the location of *MEF2C(1)* and *MEF2C(2)* targets within the *MEF2C* gene. (B) In terms of the second region of *MEF2C* investigated no obvious collective group wide differences between Control and AD at this CpG site were observed. Box plots shows median with 25th and 75th percentile as edges, the whiskers extend to the first quartile minus the interquatile range multiplied by 1.5 and up to the third quartile add the interquartile range time 1.5. Control blood *n* = 26, AD blood *n* = 25, Control brain *n* = 10, AD brain *n* = 14.](adr-1-adr170015-g003){#adr-1-adr170015-g003}

Intriguingly however, we identified a difference in methylation at this CpG in one AD patient blood sample only ([Fig. 4](#adr-1-adr170015-g004){ref-type="fig"}). The probability of observing, by chance, a value as low or lower than 70 for the AD group in the blood data was calculated using one-way analyses of variance 2.0E-10. Average methylation at the CpG of 70% was recorded for the individual M341 (blood sample). This represented a 22% reduction in methylation when compared to average methylation in blood at this site in the other samples tested (total *n* = 51). Average methylation was calculated using data obtained from at least two technical repetitions in order to exclude the possibility of a technical error. It is established that rare genetic differences within this gene can be associated with sEOAD, it could be suggested that rare epigenetic variation at this site may also associate as a risk factor.

![(A) Methylation profiling identifies rare individual AD hypomethylation of the upstream *MEF2C* CpG site. Patient sample *M341* showed statistically significant difference in methylation (*p* = 2.0E-10) when compared to other blood samples (A), statistical significance was not observed for patient *M715* in brain (B). A) Shows average methylation at the CpG investigated in each sample investigated (average of at least two runs). Controls are shown in white and AD samples in black. Error bars represent the S.E.M. Control blood = 26, AD blood *n* = 25, control brain *n* = 10, AD brain *n* = 14; Male brain *n* = 10, Female brain *n* = 14, Male blood *n* = 29 0, Female blood *n* = 22.](adr-1-adr170015-g004){#adr-1-adr170015-g004}

In order to eliminate the possibility of a genetic cause of the methylation observed in this experiment, samples were genotyped for the published GWAS SNP; no association with this genotype was found.

RIN3 3'UTR showed significant hypomethylation in AD blood but not AD brain {#sec0070}
--------------------------------------------------------------------------

RIN3 has been proven to interact with the AD associated protein BIN1, which in turn has also been significantly associated with AD via GWAS. This gene has also been shown to be differentially methylated in LOAD with an established link to AD pathology \[[@ref008]\]. We chose to investigate a CpG island identified within the 3'UTR of *RIN3* (see [Supplementary Table 1](#S1){ref-type="supplementary-material"} and [Supplementary Figure 2](#S1){ref-type="supplementary-material"}). Pyrosequencing covered seven CpGs in total within this region (shown in [Supplementary Figure 2](#S1){ref-type="supplementary-material"}) and average levels of methylation was calculated for AD blood, control blood, AD brain, and control brain ([Fig. 5](#adr-1-adr170015-g005){ref-type="fig"}) across all seven CpGs tested. AD blood samples showed hypomethylation when compared to control blood (see [Fig. 5](#adr-1-adr170015-g005){ref-type="fig"}).

![Collective group wide methylation Control versus AD for *RIN3*. Graph shows average methylation across the whole region investigated in the *RIN3* 3'UTR. Control blood *n* = 26, AD blood *n* = 22, Control brain *n* = 10, AD brain *n* = 14. Control blood Male to Female *n* = 12/14, AD blood Male to Female *n* = 15/7.](adr-1-adr170015-g005){#adr-1-adr170015-g005}

For each of the cytosines CPG1-7 data ([Fig. 6](#adr-1-adr170015-g006){ref-type="fig"}) from the blood samples, there was a significant difference between the AD and control group in % methylation (*p* \< 0.05) (CpG1 *p* = 0.019, CpG2 *p* = 0.018, CpG3 *p* = 0.012, CpG4 *p* = 0.009, CpG5 *p* = 0.002, CpG6 *p* = 0.018 and CpG7 *p* = 0.013, respectively); the AD group being lower than the control for all CPG 1--7 and there were no extreme outliers. The *p* values from the analyses were also compared to Bonferroni adjusted critical *p* values of 0.05/7 = 0.007 to adjust for the fact that 7 CGP data-sets were analyzed separately from each individual. CpG5 retained significance (*p* = 0.002) after strict Bonferroni correction for multiple comparisons, suggesting that aberrant methylation is centered within this region and spreads outwards across neighboring CpGs.

![*RIN3* Blood and Brain; resolution of each CpG. All of the seven CpG sites investigate in *RIN3* were shown to be significantly hypomethylated in AD blood (A) but not brain (B). Showing average methylation found at each CpG site in the *RIN3* 3'UTR. Control shown as a white bar (blood *n* = 26, brain *n* = 10) and AD (blood *n* = 22, brain *n* = 14) shown as a black bar. Error bars represent S.E.M.](adr-1-adr170015-g006){#adr-1-adr170015-g006}

There was no evidence (*p* \> 0.05) of a difference between groups in % methylation for any of the cytosines CPG1-7 from the brain samples. Average methylation across this region in control blood was 47.8% while average methylation in AD blood was 37.29% a reduction of 10%. No significant difference in average methylation was detected between AD brain and control brain. No link with gender was identified for overall levels of methylation at the RIN3 site; no aggregate difference could be detected between male and female samples for either blood or brain (see [Supplementary Figure 6](#S1){ref-type="supplementary-material"}).

Tissue specific hypomethylation was observed in AD brain {#sec0075}
--------------------------------------------------------

Having established that in some instances comparative regional differences in methylation may be specific to AD patients, we chose to compare relative levels of methylation between tissues tested in this study. No significant difference in methylation was observed between tissues in either control or AD samples ([Supplementary Figure 5](#S1){ref-type="supplementary-material"}) for AD and Control *PTK2*β (*p* = 0.42; *p* = 0.1)*, ABCA7* (*p* = 0.43; *p* = 0.46)*, SIRT1* (*p* = 0.06; *p* = 0.24), and *MEF2C(1)* (*p* = 0.33; *p* = 0.37) (these are the *p* values using one-tailed *T*-tests, two tailed are, for AD and control *PTK2*β (*p* = 0.85: *p* = 0.2), *ABCA7* (*p* = 0.87; *p* = 0.9), *SIRT1* (*p* = 0.13; *p* = 0.49), and *MEF2C(1)* (*p* = 0.66; *p* = 0.73). However, within the *RIN3* 3'UTR region of blood DNA was significantly hypermethylated in both AD and control blood when compared to AD and control brain ([Supplementary Figure 7](#S1){ref-type="supplementary-material"}). Hypomethylation was also observed in brain tissue for the *MEF2C(2)* site tested ([Supplementary Figure 4](#S1){ref-type="supplementary-material"}).

DISCUSSION {#sec0080}
==========

Much resource has been committed to investigating the pathogenesis of LOAD, however a comprehensive understanding of sEOAD has thus far remained elusive; it is likely that new ways of understanding drivers of sEOAD are required. Although a number of genes have been identified as drivers or causal to LOAD and fAD, those genes and associated pathways do not necessarily explain the underlying causes of sEOAD. We propose that aberrant epigenetic regulation contributes at least in part to this process for some individuals. Uncontrolled or dysregulation of a number of varied gene pathways or processes has been implicated in neurodegeneration; therefore, it is plausible that aberrant regulation of one of many genes may exacerbate pathogenesis \[[@ref005]\].

Methylation of the *SIRT1* promoter in LOAD patient samples has been previously reported by Hou et al. \[[@ref013]\]; we therefore chose to test if equivalent methylation could also be detected in sEOAD samples. It could be suggested that due to the core similarities of disease progression between AD sub-types, any epigenetic markers which are a feature of LOAD would be matched in sEOAD. Surprisingly we found no evidence of variation in levels of methylation between sEOAD samples and controls. This suggests that the methylation directed regulation of *SIRT1* is not impaired in the process of sEOAD, and the sEOAD epigenome is distinct from LOAD in at least some instances. It is not obvious how this difference impacts on the development of sEOAD, although given the role of SIRT1 in attenuating toxicities of both tau and amyloid it is likely to have some influence on the progression of disease. Further research is required to investigate the consequence of *SIRT1* regulation in both conditions.

Within our test group, we identified that the gene *MEF2C* was significantly hypomethylated in comparison to controls for only two individuals presenting with sEOAD. As an aggregate no group-wide differences could be detected, however we observed two individuals with pronounced differences in methylation within a key regulatory region of this gene (22% and 15% lower in blood and brain, respectively). The aberrant epigenetic marks recorded for this gene in this study may represent an example of a rare epi-variant risk factors existing within the population that accentuates the risk of developing sEOAD. Changes in epialleles can occur as very rare events within large populations and can have profound effects on morphology or phenotype \[[@ref039]\]. It is therefore a valid hypothesis to suggest that if the expression of the affected gene links with disease pathogenesis and levels of methylation controlling expression are altered, then this change methylation can alter the risk at the level of the individual however infrequently this may occur within a population. We evaluated the possibility that methylation at this site correlates with a known genetic risk factors however upon analysis hypomethylation did not correlate to this particular genotype.

Where tested, we observed group wide differences in the levels of promoter methylation at the *RIN3* locus between sEOAD and control samples. Intriguingly statistically significant differences in the levels of methylation were not limited to one CpG, but span a number of CpGs located within this region. The group-wide nature of these epi-polymorphisms suggests that the condition of sEOAD leads to changes in methylation at the *RIN3* locus rather than being a rarer spontaneous causative driver of disease. The equivalence in both tissue samples also supports this hypothesis, e.g., it is likely that the levels of methylation identified in leukocyte DNA are reflective of AD pathology experienced as these cells transit through the brain. Methylation of these sites is therefore likely driven by the environment of the diseased tissue, rather than methylation being causative of the disease.

The consequence of changes in the levels of methylation located with the 3'UTR of *RIN3* is unclear. RIN3 is known to associate with BIN1 and links with the process of endocytosis and Aβ processing; therefore, it is plausible that any change that impacts on regulation could exacerbate the progression of AD. One hypothesis is that the AD brain ramps up the production of *RIN3* in response to the amyloid environment via demethylation of the 3'UTR region; increased methylation within 3'UTRs associates with reduced expression in reporter assay tests \[[@ref033]\]. This is supported by the relative hypomethylation we observed in AD brain relative to blood. This may suggest a direct correlation between the length of exposure to the amyloid environment and levels of methylation for *RIN3*. Further experiments will be required to determine the consequence of 3'UTR methylation on levels of gene expression and ultimately to sEOAD pathogenesis.

Our data suggests that differences in methylation may mark the development of sEOAD. Epigenetic regulation of regions other than promoters can be aberrantly methylated in sEOAD patients promoting, initiating or driving AD pathology, suggesting that changes in epigenetic marks are a feature of the development of sEOAD. The ability to detect variations in blood allows for the testing of a large numbers of blood samples to further explore this hypothesis; an option not available if the effects manifest only in the brain epi-genome.
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